Cover Image
市場調查報告書

C型肝炎:為了帶給治療形勢革命的改變局勢的體制 - KOL的洞察

Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight

出版商 FirstWord 商品編碼 292629
出版日期 內容資訊 英文 163 pages
商品交期: 最快1-2個工作天內
價格
Back to Top
C型肝炎:為了帶給治療形勢革命的改變局勢的體制 - KOL的洞察 Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight
出版日期: 2014年04月01日 內容資訊: 英文 163 pages
簡介

本報告依據C型肝炎(HCV)中全球屈指可數的KOL獨家專訪,提供帶給目前HCV治療形勢影響的主要原因,進步及趨勢的特定與分析說明,處於後期開發階段的開發中產品和關注那些如何修正未來的HCV管理,為您概述為以下內容。

第1章 目前C型肝炎市場

  • C型肝炎概要
  • 目前治療形勢
  • 主要的C型肝炎品牌的醫療費給付
  • C型肝炎的未滿足需求

第2章 目前治療方法

  • 認證療法極為重要的臨床實驗資料
  • NS5B核苷酸(Nuc)抑制劑概要
  • NS3/NS4A蛋白分解酵素抑制劑概要
  • 干擾素及Ribavirin概要
  • Pegylated interferon-alpha(Peg-Intron, PegaSys)及Ribavirin趨勢
  • 目前治療流程

第3章 未來的C型肝炎市場

  • 未來的治療形勢
  • NS5B核苷酸(Nuc)抑制劑概要
  • NS5B非核苷酸抑制劑概要
  • NS5A複製複合體抑制劑概要
  • NS3/NS4A 蛋白分解酵素抑制劑概要
  • 未來的治療流程

第4章 C型肝炎的未來發展

  • 為了提高認識,改善診斷的教育
  • 將來發展的臨床實驗
  • 所有口服療法到2014年認可
  • 減少進入市場的拘束的價格環境
  • 有效短期療法的體製出現
  • 最終生物標記開發有助於治療

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

The December 2013 approval of Gilead's once daily oral nucleotide inhibitor Sovaldi marks a significant step in the treatment of hepatitis C (HCV). With efficacy over 90% in GT1/2/3/4 patients, this safe, best in class therapy represents a paradigm shift compared to the protease inhibitors and interferon regimens. With convenient, efficacious and safer therapies coming through the pipeline-led by Gilead, AbbVie, Bristol-Myers Squibb and Boehringer Ingelheim-the battle to transform this potentially lucrative market will be intense.

Therapy Trends: Hepatitis C is compiled from exclusive, in-depth interviews with the world's leading KOLs in HCV. It identifies and analyses the major factors, advances and trends currently influencing the HCV treatment landscape. The report focuses on late-stage pipeline products, and how these could modify future HCV management.

FirstWord selected KOLs for this report based on their level of engagement and influence within the HCV pharmaceutical industry, and on their scientific standing. Our unique KOL scoring system identifies those thought-leaders with the greatest insight into how HCV clinical research will shape the future market.

Therapy Trends: Hepatitis C -- Game changing regimens to revolutionise treatment landscape examines the most prominent insights gained from the field's key opinion leaders. The results of FirstWord's research and analysis will help you to:

  • Comprehend the current trends driving and shaping the global HCV market
  • Understand the future landscape and how new classes will fit into the treatment algorithm
  • Assess the commercial and clinical potential of the pipeline nucs, non-nucs, NS5A inhibitors and next generation protease inhibitors
  • Develop planning strategies based on KOL insight
  • Identify the unmet needs and opportunities for disease management
  • Evaluate the performance of companies with the most robust new product pipelines
  • Recognise the key factors KOLs predict will drive future treatment trends

Critical Questions Answered

The hepatitis C (HCV) market is expected to become one of the fastest growing markets in Pharma over the next decade given a sizable 170 million patient population, a significant unmet need and rapid advancements in the clinic. The management of this infectious disease is on the edge of a revolution that will bring considerable changes to the treatment algorithm. KOLs from North America and Europe provide answers to some critical questions regarding the global HCV market, including:

list> What do KOLs make of the Sovaldi and Olysio and their impact on treatment? What are the current unmet needs and major challenges in HCV treatment? What are the most promising late-stage classes in development? Which therapies are KOLs eagerly awaiting? How will the nucleotide inhibitors, non-nucs, and NS5A inhibitors be positioned in the HCV market? How do the second generation protease inhibitors differ from their first-generation cousins? In what ways could eventual biomarkers improve future HCV disease management? How will treatment of HCV look in the future? How do KOLs think the pricing environment will shape the uptake of new HCV treatments? What clinical research trends do KOLs predict for future HCV therapies?

Table of Contents

1. Current Hepatitis C marketplace

  • Hepatitis C overview
  • Current treatment landscape
  • Reimbursement of key Hepatitis C brands
  • Unmet needs in Hepatitis C

2. Current therapies

  • Pivotal trial data of approved therapies
  • NS5B nucleoside (Nuc) inhibitors overview
    • Sovaldi (sofosbuvir; Gilead Sciences) trends
  • NS3/NS4A Protease inhibitor overview
    • Olysio (simeprevir; Medivir/Janssen) trends
    • Incivek/Incivo (telaprevir; Vertex's/ Janssen/Mitsubishi Tanabe) trends
    • Victrelis (boceprevir; Merck) trends
  • Interferon and Ribavirin Overview
  • Pegylated interferon-alpha (Peg-Intron, PegaSys) and ribavirin trends
  • Current treatment algorithm

3. Future Hepatitis C marketplace

  • Future treatment landscape
  • NS5B nucleoside (Nuc) inhibitors overview
    • Mericitabine (RO5024048; Roche/Gilead) trends
    • BMS-986094 (formally INX-189; Bristol Myers Squib) trends
  • NS5B non-nucleoside inhibitor overview
    • BI-201127 (Boehringer Ingelheim) trends
    • ABT-333 (AbbVie) trends
    • ABT-072 (AbbVie) trends
    • VX-222 (Vertex) trends
    • Tegobuvir (GS-9190; Gilead) trends
  • NS5A replication complex inhibitor overview
    • Daclatasvir (BMS-790052; Bristol-Myers Squibb) trends
    • GS-5885 (Gilead Sciences) trends
    • ABT-267 (AbbVie) trends
    • ACH-3102 (Achillion) trends
  • NS3/NS4A protease inhibitor overview
    • Faldaprevir (BI-201335; Boehringer Ingelheim) trends
    • ABT-450 (AbbVie/Enanta) trends
    • Asunaprevir (BMS-650032; Bristol-Myers Squibb) trends
    • Danoprevir (RO5190591; Roche) trends
    • Sovaprevir (ACH-1625; Achillion Pharmaceuticals) trends
    • Vaniprevir (MK-7009; Merck) trends
    • MK-5172 (Merck) trends
  • Future treatment algorithm

4. Future developments in Hepatitis C

  • Education to raise awareness and improve diagnosis
  • Clinical trials will evolve in the future
  • All oral regimen will be approved by 2014
  • Constrained pricing environments will reduce market access
  • Effective shorter treatment regimes will emerge
  • Eventual development of biomarkers will aid treatment
Back to Top